Drugging RAS: Know the enemy
Abstract
The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 17, 2017
- Source ID
- 10.1126/science.aam7622
Entities
People
- Bjoern Papke
- Channing Der
Organizations
- German Research Foundation
- Lustgarten Foundation for Pancreatic Cancer Research
- National Cancer Institute
- Pancreatic Cancer Action Network
- United States Department of Defense
- University of North Carolina at Chapel Hill